Seres Therapeutics Inc (MCRB)
0.8166
+0.02
(+2.70%)
USD |
NASDAQ |
Nov 05, 16:00
0.8166
0.00 (0.00%)
After-Hours: 18:07
Seres Therapeutics Enterprise Value: 151.90M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 151.90M |
| November 01, 2024 | 155.97M |
| October 31, 2024 | 155.65M |
| October 30, 2024 | 150.04M |
| October 29, 2024 | 148.26M |
| October 28, 2024 | 137.47M |
| October 25, 2024 | 138.22M |
| October 24, 2024 | 139.01M |
| October 23, 2024 | 146.12M |
| October 22, 2024 | 149.99M |
| October 21, 2024 | 154.71M |
| October 18, 2024 | 159.81M |
| October 17, 2024 | 159.19M |
| October 16, 2024 | 159.11M |
| October 15, 2024 | 155.00M |
| October 14, 2024 | 158.09M |
| October 11, 2024 | 153.66M |
| October 10, 2024 | 148.09M |
| October 09, 2024 | 143.98M |
| October 08, 2024 | 148.29M |
| October 07, 2024 | 156.90M |
| October 04, 2024 | 160.01M |
| October 03, 2024 | 158.29M |
| October 02, 2024 | 168.17M |
| October 01, 2024 | 177.12M |
| Date | Value |
|---|---|
| September 30, 2024 | 174.81M |
| September 27, 2024 | 170.69M |
| September 26, 2024 | 157.50M |
| September 25, 2024 | 170.14M |
| September 24, 2024 | 199.68M |
| September 23, 2024 | 207.27M |
| September 20, 2024 | 202.72M |
| September 19, 2024 | 190.58M |
| September 18, 2024 | 190.58M |
| September 17, 2024 | 198.17M |
| September 16, 2024 | 186.03M |
| September 13, 2024 | 182.87M |
| September 12, 2024 | 176.92M |
| September 11, 2024 | 190.58M |
| September 10, 2024 | 187.54M |
| September 09, 2024 | 187.54M |
| September 06, 2024 | 176.00M |
| September 05, 2024 | 167.82M |
| September 04, 2024 | 155.64M |
| September 03, 2024 | 150.11M |
| August 30, 2024 | 152.74M |
| August 29, 2024 | 151.13M |
| August 28, 2024 | 153.98M |
| August 27, 2024 | 157.20M |
| August 26, 2024 | 164.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
51.46M
Minimum
Jun 14 2022
3.170B
Maximum
Nov 17 2020
648.60M
Average
391.84M
Median
Mar 09 2022
Enterprise Value Benchmarks
| Chimerix Inc | -59.43M |
| Cellectar Biosciences Inc | 64.32M |
| Marinus Pharmaceuticals Inc | 10.41M |
| Jaguar Health Inc | 26.16M |
| PDS Biotechnology Corp | 85.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.87M |
| Total Expenses (Quarterly) | 31.34M |
| EPS Diluted (Quarterly) | -0.22 |
| Earnings Yield | -144.5% |
| Normalized Earnings Yield | -110.21 |